Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half‐life (t1/2) and the clearance (Cl) are 3.3‐fold longer and 3.7‐fold …

Objectives: To examine pediatric intensivist sedation management, sleep promotion, and
delirium screening practices for intubated and mechanically ventilated children. Design: An …

Midazolam is a drug with actions towards the central nervous system producing sedative
and anticonvulsants effects, used for sedation and seizures treatments. A better …

Background Large animal models are an essential tool in the development of rationally-
based new clinical therapies for preterm infants. We provide a description of the newborn …

Aims Inflammation and organ failure have been reported to have an impact on cytochrome
P450 (CYP) 3A‐mediated clearance of midazolam in critically ill children. Our aim was to …

Background: although neonatal pain management has seen huge improvements in the past
years, many gaps between knowledge and practice still exist. Objective: to give the reader …

Endocrine control of cardiovascular function is probably immature in the preterm infant; thus,
it may contribute to the relative ineffectiveness of current adrenergic treatments for preterm …

The developing brain, particularly in premature infants, is highly susceptible to
environmental and pharmacological influences. Premature neonates often require …

Purpose The aim of the present study was to develop a population pharmacokinetic model
of midazolam, and to evaluate the influence of maturation process and other variability …

Growth and development affect drug‐metabolizing enzyme activity thus could alter the
metabolic profile of a drug. Traditional studies to create metabolite profiles and study the …